Menlo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Menlo Therapeutics's estimated annual revenue is currently $10.6M per year.
- Menlo Therapeutics's estimated revenue per employee is $3,546,667
- Menlo Therapeutics's total funding is $159.8M.
Employee Data
- Menlo Therapeutics has 3 Employees.
- Menlo Therapeutics grew their employee count by 0% last year.
What Is Menlo Therapeutics?
We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
keywords:N/A
$159.8M
Total Funding
3
Number of Employees
$10.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Menlo Therapeutics News
The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo...
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged...
The Menlo Park biotech raised $69 million in an offering that priced in the middle of its target range but sold 900,000 more shares than...
Janus Henderson Group PLC lowered its position in Menlo Therapeutics Inc (NASDAQ:MNLO) by 0.5% during the 2nd quarter, according to ...
JPMorgan Chase & Co. reduced its position in shares of Menlo Therapeutics Inc (NASDAQ:MNLO) by 4.1% in the 2nd quarter, according to the ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.2M | 3 | N/A | N/A |
#2 | $0.2M | 3 | N/A | N/A |
#3 | $0.2M | 3 | N/A | N/A |
#4 | $0.2M | 3 | N/A | N/A |
#5 | $0.2M | 3 | N/A | N/A |